ANL 11.20 Decreased By ▼ -0.25 (-2.18%)
ASC 9.71 Decreased By ▼ -0.09 (-0.92%)
ASL 12.00 Increased By ▲ 0.65 (5.73%)
AVN 80.00 Increased By ▲ 1.70 (2.17%)
BOP 5.94 Increased By ▲ 0.11 (1.89%)
CNERGY 5.70 Increased By ▲ 0.16 (2.89%)
FFL 6.85 Decreased By ▼ -0.12 (-1.72%)
FNEL 6.26 Increased By ▲ 0.11 (1.79%)
GGGL 12.10 Decreased By ▼ -0.05 (-0.41%)
GGL 16.89 Increased By ▲ 0.07 (0.42%)
GTECH 9.45 Decreased By ▼ -0.20 (-2.07%)
HUMNL 7.00 Increased By ▲ 0.35 (5.26%)
KEL 2.68 Increased By ▲ 0.12 (4.69%)
KOSM 3.09 Increased By ▲ 0.09 (3%)
MLCF 27.50 Increased By ▲ 0.25 (0.92%)
PACE 3.09 Decreased By ▼ -0.01 (-0.32%)
PIBTL 5.99 Decreased By ▼ -0.12 (-1.96%)
PRL 17.58 Decreased By ▼ -0.30 (-1.68%)
PTC 7.62 Decreased By ▼ -0.53 (-6.5%)
SILK 1.29 Decreased By ▼ -0.14 (-9.79%)
SNGP 27.40 Increased By ▲ 1.31 (5.02%)
TELE 11.64 Decreased By ▼ -0.12 (-1.02%)
TPL 9.90 Increased By ▲ 0.01 (0.1%)
TPLP 18.62 Increased By ▲ 0.94 (5.32%)
TREET 29.70 Decreased By ▼ -0.40 (-1.33%)
TRG 81.11 Decreased By ▼ -0.57 (-0.7%)
UNITY 22.48 Decreased By ▼ -0.79 (-3.39%)
WAVES 13.45 Decreased By ▼ -0.05 (-0.37%)
WTL 1.56 Decreased By ▼ -0.04 (-2.5%)
YOUW 5.09 Decreased By ▼ -0.01 (-0.2%)
BR100 4,262 Increased By 29.5 (0.7%)
BR30 15,499 Increased By 12.7 (0.08%)
KSE100 42,861 Increased By 319.7 (0.75%)
KSE30 16,276 Increased By 133.1 (0.82%)
Pakistan

COVID-19 vaccine: Chinese company seeks permission for clinical trials in Pakistan

  • The company has contacted the Drug Regulatory Authority Pakistan (DRAP) and expressed its desire for clinical trials of COVID-19 in Pakistan.
  • The clinical trials of the vaccine would be carried out in collaboration with a local pharma company, stated in the letter
26 Dec, 2020

Another Chinese pharma company, Zafai Longcom, has expressed interest in clinical trials of the COVID-19 vaccine in Pakistan.

According to ARY news, the company has contacted the Drug Regulatory Authority Pakistan (DRAP) and expressed its desire for clinical trials of COVID-19 in Pakistan.

The Chinese company has requested the DRAP for cooperation in this regard.

The letter, which was sent to DRAP, reads that that Zafai Longcom is a local pharmaceutical company in the Chinese province of Inoue, which has developed the corona vaccine in collaboration with the Chinese Academy of Sciences, and now wants clinical trials of possible vaccines in Pakistan.

The clinical trials of the vaccine would be carried out in collaboration with a local pharma company, stated in the letter. For the trials, the company wanted to transfer vaccines and test kits to Pakistan.

The company is currently testing its vaccine on 29,000 volunteers.

It may be noted that before this company, another Sinopharma of China has also conducted its clinical trials in Pakistan.

Federal Minister for Planning and Development Asad Umar earlier had said that Pakistan is all set to participate in the Phase 3 trials of a Chinese developed coronavirus vaccine.

Comments

Comments are closed.